Fate Therapeutics (FATE) Revenue (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Revenue came in at $1.3 million in Q1 2026, down 20.26% YoY from $1.6 million in Q1 2025, and down 5.11% on a QoQ basis from $1.4 million in Q4 2025.
Fate Therapeutics (FATE) Revenue (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of Revenue data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Revenue fell 20.26% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 52.64% YoY) and the FY2025 annual result came in at $6.6 million, down 51.24% from the prior year.
- Revenue eased to $1.3 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $59.0 million in Q1 2023 to a low of $933000.0 in Q2 2023.
- A 5-year average of $10.7 million and a median of $1.9 million in 2024 frame the typical range for Revenue.
- The widest YoY moves for Revenue: up 625.83% in 2024, down 96.74% in 2024.
- Tracing FATE's Revenue over 5 years: stood at $44.4 million in 2022, then tumbled by 96.22% to $1.7 million in 2023, then grew by 10.98% to $1.9 million in 2024, then declined by 26.4% to $1.4 million in 2025, then retreated by 5.11% to $1.3 million in 2026.
- The last three Revenue figures came in at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 1.37 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 6.77 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 933,000.00 |
| Mar 31, 2023 | 58.98 Mn |
| Dec 31, 2022 | 44.36 Mn |
| Sep 30, 2022 | 14.98 Mn |
| Jun 30, 2022 | 18.55 Mn |
| Mar 31, 2022 | 18.41 Mn |
| Dec 31, 2021 | 17.07 Mn |
| Sep 30, 2021 | 14.23 Mn |
| Jun 30, 2021 | 13.41 Mn |